|
USP47 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.92559995621156E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.82639999965784E-07 |
| Normal-vs-Stage2 |
5.190000E-04 |
| Normal-vs-Stage3 |
1.37629996288524E-09 |
| Normal-vs-Stage4 |
1.57839963321749E-10 |
| Stage1-vs-Stage2 |
6.011800E-01 |
| Stage1-vs-Stage3 |
3.291700E-02 |
| Stage1-vs-Stage4 |
3.195900E-03 |
| Stage2-vs-Stage3 |
5.123800E-02 |
| Stage2-vs-Stage4 |
1.083950E-02 |
| Stage3-vs-Stage4 |
4.008000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.91990045662305E-10 |
| Normal-vs-AfricanAmerican |
3.224100E-03 |
| Normal-vs-Asian |
1.6962299999923E-05 |
| Caucasian-vs-AfricanAmerican |
3.506400E-01 |
| Caucasian-vs-Asian |
3.681200E-01 |
| AfricanAmerican-vs-Asian |
7.136200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.89880000003961E-08 |
| Normal-vs-Female |
1.79289999513443E-08 |
| Male-vs-Female |
6.287800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.16890000029835E-07 |
| Normal-vs-Age(41-60Yrs) |
2.55140000016141E-07 |
| Normal-vs-Age(61-80Yrs) |
4.34040003938208E-09 |
| Normal-vs-Age(81-100Yrs) |
1.777100E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.431400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.179390E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.117780E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.188800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.925960E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.921200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.968000E-02 |
| Classical-VS-Follicular |
6.431000E-01 |
| Classical-VS-Other |
2.512400E-01 |
| Classical-VS-Normal |
4.23999999554781E-08 |
| Tall-VS-Follicular |
1.212240E-02 |
| Tall-VS-Other |
9.553800E-01 |
| Tall-VS-Normal |
2.66320000497089E-08 |
| Follicular-VS-Other |
2.884400E-01 |
| Follicular-VS-Normal |
2.642100E-04 |
| Other-VS-Normal |
1.617390E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.40940000004086E-07 |
| Normal-vs-N1 |
4.91359997134566E-09 |
| N0-vs-N1 |
7.048400E-02 |
|
|
